HC Wainwright Forecasts Omeros’ Q3 Earnings (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Omeros in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($0.05) per share for the quarter, up from their prior estimate of ($0.22). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for Omeros’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $0.24 EPS and FY2028 earnings at $1.63 EPS.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million.

A number of other research analysts have also recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Tuesday, April 21st. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Omeros Stock Up 1.0%

OMER stock opened at $17.36 on Monday. Omeros has a twelve month low of $3.94 and a twelve month high of $18.14. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of 13.56 and a beta of 2.54. The business’s fifty day simple moving average is $11.04 and its two-hundred day simple moving average is $11.58.

Insiders Place Their Bets

In other news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the transaction, the director owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. This represents a 17.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO David J. Borges sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total value of $84,750.00. Following the transaction, the chief accounting officer owned 5,000 shares in the company, valued at approximately $84,750. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. UBS Group AG boosted its stake in shares of Omeros by 213.5% during the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after purchasing an additional 1,513,893 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Omeros by 85.2% during the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock worth $1,897,000 after buying an additional 82,646 shares during the period. Corient Private Wealth LLC boosted its position in Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after acquiring an additional 79,263 shares in the last quarter. AlphaQuest LLC boosted its position in Omeros by 8,259,600.0% during the 4th quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock valued at $1,419,000 after acquiring an additional 82,596 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after acquiring an additional 666,357 shares during the period. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.